Triweekly docetaxel versus biweekly docetaxel as a treatment for advanced castration resistant prostate cancer
- Kellokumpu-Lehtinen, P. (Contributor)
- U Harmberg (Contributor)
- P Hervonen (Contributor)
- T Joensuu (Contributor)
- R McDermont (Contributor)
- C Ginman (Contributor)
- M Luukkaa (Contributor)
- P Nyandoto (Contributor)
- A Hemminki (Contributor)
- S Nilsson (Contributor)
- J McCaffrey (Contributor)
- R Asola (Contributor)
- T Turpeenniemi-Hujanen (Contributor)
- F Laestadius (Contributor)
- T Tasmuth (Contributor)
- K Sandberg (Contributor)
- M Keane (Contributor)
- I Lehtinen (Contributor)
- Luukkaala, T. (Contributor)
- H Joensuu (Contributor)
Aktiviteetti: Konferenssiesitelmä